Jay Shukert

Triumvirate Environmental (Florida), Inc. operates hazardous waste facilities. The company is headquartered in Davie, FL.

Siesta Medical, Inc. develops surgical implants and tools for the treatment of obstructive sleep apnea. It offers airlift procedure that include hyoid and tongue suspension. The Company was founded by Peter Martin, Erik van der Burg, Chris Feezor and Michael Kolber in 2009 and is headquartered in Los Gatos, CA.

Evera Medical, based in Foster City, California, is a medical device company focused on developing and commercializing novel biomaterials for tissue reconstruction, repair and augmentation. Evera use materials whose clinical safety and biocompatibility has been long established. By combining these materials in a proprietary fashion, Evera implants are meant to provide strong support, yet mimic the compliant nature of human tissue.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL.

Neurex Corporation is a developmental biopharmaceutical company focused on acute care therapeutics for the treatment of diverse neurological and cardiovascular indications.

CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases

Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds.